The page below is a sample from the LabCE course Breast Cancer Predictive Markers. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Breast Cancer Predictive Markers (online CE course) »
How to Subscribe
Histology CE Package$65 Add to cart
Individual course$20 Add to cart

Only patients who over-express HER2 (eg, positive scores by IHC, CISH, or FISH) are candidates to receive Herceptin® (trastuzumab) treatment.

Select true or false